Evidence map›Paper›PMID 40865105›Full record

ReviewBiomedica : revista del Instituto Nacional de Salud2025

Is meningococcal B vaccination needed in the post-COVID-19 world?

Amanda Izeli Portilho, Elizabeth De Gaspari

Abstract readReview
In one paragraph

Review in Biomedica : revista del Instituto Nacional de Salud, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Amanda Izeli PortilhoCentro de Imunologia do Instituto Adolfo Lutz, São Paulo, SP, Brasil; Programa de Pós-Graduação Interunidades em Biotecnologia, Universidade de São Paulo, São Paulo, SP, Brasil.ORCID 0000-0003-0875-5910
Elizabeth De GaspariCentro de Imunologia do Instituto Adolfo Lutz, São Paulo, SP, Brasil; Programa de Pós-Graduação Interunidades em Biotecnologia, Universidade de São Paulo, São Paulo, SP, Brasil.ORCID 0000-0001-8332-2248

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neisseria meningitidis is the main cause of bacterial meningitis worldwide and is transmitted through respiratory secretions. Meningitis is a serious public health problema because of its high morbidity and mortality rates and the risk of causing epidemics. Although vaccines are available to prevent meningococcal disease, serogroup B infections are still challenging, given that many countries do not include meningococcal B vaccines in their national immunization programs. In addition, recent data suggests somewhat sustained N. meningitidis B infections during the COVID-19 pandemic and increasing levels of meningococcal disease after its control. These findings agree with previous observations indicating that respiratory viruses facilitate respiratory bacterial infections. This essay intends to present epidemiological data on meningococcal disease and discusses studies exploring why the prevention of bacterial and viral infections is an intricate subject.

Indexed as

COVID-19Meningitis, MeningococcalMeningococcal InfectionsMeningococcal VaccinesNeisseria meningitidis, Serogroup BGlobal HealthHumansPandemicsSARS-CoV-2VaccinationMeningococcal Vaccinescoronavirus infectionsmeningococcal diseaseNeisseria meningitidisrespiratory infections

Identifiers

PMID40865105
PMCPMC12482904

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.